CYTOCHROME P450 PHARMACOGENETICS AS A PREDICTOR OF TOXICITY AND CLINICAL EFFICAC
CYTOCHROME P450 PHARMACOGENETICS AS A PREDICTOR OF TOXICITY AND CLINICAL EFFICAC
批准号:
7717528
负责人:
Bryan Paul Schneider
金额:
$0.02万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-12-01 至 2008-05-31
关键词:
AgeAnthracycline AntibioticsAnthracyclinesCardiacClinicalCohort StudiesComputer Retrieval of Information on Scientific Projects DatabaseCyclophosphamideCytochrome P450DoseDoxorubicinEnzymesExcretory functionFertilityFunctional disorderFundingGenetic PolymorphismGenetic VariationGenotypeGoalsGrantHot flushesInstitutionInvasiveLupus NephritisMenopausal hot flushesMetabolismNausea and VomitingPatientsPharmaceutical PreparationsPharmacogeneticsPremature MenopausePremature Ovarian FailurePremenopauseReproductionResearchResearch PersonnelResourcesRoleSecondary toSocial ImpactsSourceStandards of Weights and MeasuresThrombocytopeniaToxic effectUnited States National Institutes of HealthWomanbonecohortcytotoxichormone therapymalignant breast neoplasmreproductive
中文摘要
这个子项目是许多研究子项目中利用
资源由NIH/NCRR资助的中心拨款提供。子项目和
调查员(PI)可能从NIH的另一个来源获得了主要资金,
并因此可以在其他清晰的条目中表示。列出的机构是
该中心不一定是调查人员的机构。
无论有没有额外的细胞毒性或激素治疗,联合使用蒽环类药物和环磷酰胺是女性浸润性乳腺癌常见的标准治疗方法。不幸的是,并不是所有的女性都能用这种方法长期存活,而且毒性很常见。育龄妇女特别关注的一个问题是,治疗会导致生育能力的永久性丧失。除了过早绝经对生殖的心理社会影响外,其他相关的负面后遗症包括潮热和可能与骨骼相关的不良后果。阿霉素的具体毒性包括恶心和呕吐、肌抑制、血小板减少和心功能不全(与剂量相关)。虽然多种因素都会影响治疗的有效性和毒性,但其中一个重要的变量是宿主代谢和清除化合物的能力。因此,除了选择的药物和给药的总剂量外,改变化疗药物新陈代谢和排泄的细胞色素P450(CYP450)酶的多态性可能会影响疗效和毒性。先前的一项回顾性队列研究确定了用单药环磷酰胺治疗的狼疮性肾炎患者中预测卵巢早衰的选定的CYP450酶基因。这项研究的目的是描述在一组患有早期乳腺癌的绝经前妇女中,基因变异在过早绝经、潮热和其他毒性反应中的作用。
英文摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
The combination of an anthracycline and cyclophosphamide with or without additional cytotoxic or hormonal therapy represents a common standard approach to therapy in women with invasive breast cancer. Unfortunately, not all women enjoy long term survival with this approach and toxicity is common. A particular concern among women of reproductive age is the permanent loss of fertility secondary to therapy. In addition to the psycho-social impact of premature menopause with regard to reproduction, other associated negative sequelae include hot flashes and possible adverse bone-related consequences. The specific toxicities of doxorubicin include nausea and vomiting, mylosuppression, thrombocytopenia, and cardiac dysfunction (dose-related). While multiple factors influence both the efficacy and the toxicity of therapy, one important variable is the ability of the host to metabolize and clear a compound. Thus, in addition to the agent selected and the total dose administered, polymorphisms of the cytochrome P450 (CYP450) enzymes that alter the metabolism and excretion of chemotherapeutic drugs may have an impact on efficacy and toxicity. A prior retrospective, cohort study identified selected CYP450 enzyme genotypes which predicted for premature ovarian failure in lupus nephritis patients treated with single agent cyclophosphamide. The goal of this study is to delineate the role of genetic variations in premature menopause, hot flashes, and other toxicities in a cohort of premenopausal women with early breast cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
VEGF Gene Amplification/Haplotype as Biomarkers for Bevacizumab in Breast Cancer
-
批准号:8518270
-
项目类别:
-
资助金额:$30.34万
-
财政年份:2011
-
负责人:Bryan Paul Schneider
-
依托单位:
VEGF Gene Amplification/Haplotype as Biomarkers for Bevacizumab in Breast Cancer
-
批准号:8116378
-
项目类别:
-
资助金额:$33.61万
-
财政年份:2011
-
负责人:Bryan Paul Schneider
-
依托单位:
PILOT EVALUATION OF THE ROLE OF POLYMORPHISMS OF ANGIOGENESIS GENES IN BREAST
-
批准号:7717544
-
项目类别:
-
资助金额:$0.97万
-
财政年份:2007
-
负责人:Bryan Paul Schneider
-
依托单位:
海外基金